Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

L. Varga, E. Czink, Z. S. Miszlai, K. Pálóczi, A. Banyai, G. Szegedi, G. Füst

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic lymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course of the disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P <0.01) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B, long-term survivors who died ≥ 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group A (P = 0.002), and a similar but less pronounced difference was found in C3 levels (P = 0.055). These differences were even more marked (P = 0.0006 and P = 0.0015, vely) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2-3 with low (<mean - 2 s.d. of the normal values), and normal CP levels survived for 2.0 ± 1.1, and 4.6 ± 3.0 years, respectively. All the nine and 11/13 patients with low CP and C4 levels, respectively, died within 3 years after the complement measurements were made. These findings indicate that complement measurements performed in CLL patients have a clinical value.

Original languageEnglish
Pages (from-to)112-116
Number of pages5
JournalClinical and Experimental Immunology
Volume99
Issue number1
Publication statusPublished - 1995

Fingerprint

Classical Complement Pathway
B-Cell Chronic Lymphocytic Leukemia
Survival
Survivors
Alternative Complement Pathway
Antigen-Antibody Complex

Keywords

  • C3
  • C4
  • chronic lymphocytic leukaemia
  • classical pathway
  • predictive marker
  • serum complement

ASJC Scopus subject areas

  • Immunology

Cite this

@article{7c670c4771774752a749e0a8417c709d,
title = "Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia",
abstract = "The activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic lymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course of the disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P <0.01) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B, long-term survivors who died ≥ 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group A (P = 0.002), and a similar but less pronounced difference was found in C3 levels (P = 0.055). These differences were even more marked (P = 0.0006 and P = 0.0015, vely) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2-3 with low (",
keywords = "C3, C4, chronic lymphocytic leukaemia, classical pathway, predictive marker, serum complement",
author = "L. Varga and E. Czink and Miszlai, {Z. S.} and K. P{\'a}l{\'o}czi and A. Banyai and G. Szegedi and G. F{\"u}st",
year = "1995",
language = "English",
volume = "99",
pages = "112--116",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

AU - Varga, L.

AU - Czink, E.

AU - Miszlai, Z. S.

AU - Pálóczi, K.

AU - Banyai, A.

AU - Szegedi, G.

AU - Füst, G.

PY - 1995

Y1 - 1995

N2 - The activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic lymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course of the disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P <0.01) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B, long-term survivors who died ≥ 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group A (P = 0.002), and a similar but less pronounced difference was found in C3 levels (P = 0.055). These differences were even more marked (P = 0.0006 and P = 0.0015, vely) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2-3 with low (

AB - The activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic lymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course of the disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P <0.01) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B, long-term survivors who died ≥ 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group A (P = 0.002), and a similar but less pronounced difference was found in C3 levels (P = 0.055). These differences were even more marked (P = 0.0006 and P = 0.0015, vely) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2-3 with low (

KW - C3

KW - C4

KW - chronic lymphocytic leukaemia

KW - classical pathway

KW - predictive marker

KW - serum complement

UR - http://www.scopus.com/inward/record.url?scp=0028941263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028941263&partnerID=8YFLogxK

M3 - Article

C2 - 7813102

AN - SCOPUS:0028941263

VL - 99

SP - 112

EP - 116

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -